Artemether topical - EpiPharm

Drug Profile

Artemether topical - EpiPharm

Alternative Names: EPI SK14

Latest Information Update: 26 Aug 2015

Price : $50

At a glance

  • Originator EpiPharm
  • Class Anthelmintics; Antifungals; Antimalarials; Antiprotozoals; Artemisinins; Fluorenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Mitochondrial protein inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Seborrhoeic keratosis

Most Recent Events

  • 01 Jul 2015 EpiPharm completes a phase II trial in Seborrhoeic keratosis in Switzerland (ISRCTN12424904)
  • 20 Feb 2015 Phase-II clinical trials in Seborrhoeic keratosis in Switzerland (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top